Australia

Recce Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Recce Pharmaceuticals Announces Positive Data Against Streptococcus Pneumoniae Sinusitis Infection in Animal Model

Lead Product(s): R327

Therapeutic Area: Infections and Infectious Diseases Product Name: R327

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2021

Details:

RECCE® 111 is a non-descript title for an experimental compound, developed in-house, building upon the unique mechanisms of action of RECCE® 327. Positive sinusitis infection data indicated in animal study.

Uniquest

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Alterity and UniQuest to Reverse Bacterial Resistance to Antibiotics

Lead Product(s): PBT2

Therapeutic Area: Infections and Infectious Diseases Product Name: PBT2

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Alterity Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership December 21, 2020

Details:

The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.

Immuron

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

BIO Digital 2021

Participation Not Confirmed

Update your events

Immuron SARS-CoV-2 Research Agreement with Monash University

Lead Product(s): IMM-124E

Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Monash University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 15, 2020

Details:

A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E).